Systemic sclerosis & Raynaud's
Obinutuzumab in systemic sclerosis: a multicentre retrospective case series
Authors' conclusion
OBZ may represent a valuable therapeutic option in SSc, particularly in patients with RTX intolerance or inadequate response. Meaningful clinical benefit was observed even in advanced, non-inflammatory phenotypes; whether deeper, tissue-level B-cell depletion contributes to this benefit remains a hypothesis to be investigated prospectively.
Study context
- Population
- Multi-refractory patients with systemic sclerosis (SSc) previously treated by Rituximab (RTX), treated with obinutuzumab (OBZ)patients with SSc treated with OBZ
- Participants
- 5 patients
- Outcome
- Tolerability
- Follow-up
- Median 12 months
Methodological detailsreal-life
- Real-life
Main finding
As reported in the abstract
- OBZ was well tolerated, without allergic cross-reaction or serious adverse events
Observational data: associations, not effects.
Further findings
Complete peripheral CD19+ B-cell depletion
- Achieved in all patients
Gamma-globulin levels, median
g/L
- Before
- 11.7
- After
- 8.8
Skin fibrosis, median mRSS
- Before
- 27 (range 4-31)
- After
- 8 (range 0-23)
Articular remission
- Achieved in all assessable patients
Lung parenchymal disease in SSc-interstitial lung disease patients
- Remained stable on functional assessment and imaging across 3 SSc-interstitial lung disease patients
Corticosteroid dose, median per day
mg
- Before
- 10 (range 0-20)
- After
- 5 (range 0-10)
- Reduced or stabilised in all patients
Prior immunosuppressive therapies
- Median number of prior therapies
- five
- RTX stopped because of allergic reactions
- 4/5
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →